Triple-negative breast cancer (TNBC) is immunohistochemically defined as lacking expression of estrogen and progesterone receptors (ER, PR) and absence of over-expression of human epidermal growth factor receptor 2 (HER-2), and represents 10-20% of all cases of the disease [1, 2]. This evidence concerns the gene PGR and triple-negative breast carcinoma.